Activating receptor on cytokine-induced killer cell (NKG2D, NKp30, DNAM-1, etc.)

Activating receptors on cytokine-induced killer cells comprise a group of surface molecules, most notably NKG2D, DNAM-1, and NKp30, that enable CIK cells to recognize and destroy malignant or infected cells independent of classical MHC pathways. These receptors are essential for the non-specific, rapid cytotoxic function of CIK cells, rendering them effective in tumor immunotherapy and some infectious diseases. They interact with stress-induced ligands overexpressed on diseased but not healthy cells and facilitate immune activation, cell signaling, and target cell lysis. Targeting these receptors with cell therapies or enhancing their activity is a promising strategy in cancer treatment, though safety and specificity must be carefully managed.

Other names

Activating receptors on cytokine-induced killer cellsCIK cell activating receptorsNatural killer cell activating receptors (in context of CIK phenotype)NKG2DNKp30DNAM-1

Drug/cell therapy products that activate, upregulate, or co-stimulate these receptors (e.g., through cytokine induction or genetic engineering) enhance CIK cell antitumor or antiviral activity.